Bayer Schering to Conduct Phase IV Hypertension trial in China

Bayer Schering Pharma announced it is beginning a Phase IV trial among an Asia Pacific population that combines two blood pressure medications: Adalat, Bayer Schering’s calcium channel blocker (CCB), and valsartan, an angiotensin receptor blocker (ARB) marketed by Novartis under the name Diovan. The goal is to produce lower blood pressure readings than a high dose of valsartan alone. More details... Stock Symbol: (NYSE: NVS)